|Bid||42.50 x 800|
|Ask||45.00 x 1100|
|Day's Range||42.33 - 44.43|
|52 Week Range||27.87 - 60.67|
|Beta (5Y Monthly)||1.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2021 - Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.14|
Aby Mathew, EVP And Chief Scientific Officer at Biolife Solutions (NASDAQ:BLFS), made a large buy and sell of company shares on October 20, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Aby Mathew exercised options to purchase 20,000 Biolife Solutions shares at a price of $1.64 per share for a total of $32,800 on October 20. They then sold their shares on succeeding transactions in the open market. They sold at prices r
One unsung hero in the effort is a small company helping facilitate the production of cell and gene therapies called BioLife Solutions (NASDAQ: BLFS). It creates, builds, and sells tools for bioproduction to the cell and gene therapy (CGT) industry.
Joseph C Schick, Director at Biolife Solutions (NASDAQ:BLFS), made a large insider sell on October 7, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Schick sold 3,250 shares of Biolife Solutions at prices ranging from $39.96 to $40.28. The total transaction amounted to $130,145. Following the transaction, Schick still owns 8,625 shares of the company, worth $335,253. Biolife Solutions shares are trading up 1.